Matthew Wicklund, MD
Neuromuscular Medicine · San Antonio, TXNPI 1255312161
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $95,587 of the $110,490 with a category attached, or 86.5%. 13 manufacturers reported payments, led by Sarepta Therapeutics, Inc. at 58.0% of the total.
Across 90 payments — averaging $1227.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sarepta Therapeutics, Inc.$64K
- Amicus Therapeutics, Inc.$19K
- Sanofi$11K
- Spark Therapeutics, Inc.$7K
- UCB, Inc.$3K
- Lupin Inc.$3K
- plus $4K from 7 others
Across 39 payments — averaging $3845.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$80K
- Harmony Biosciences LLC$42K
- Takeda Pharmaceuticals U.S.A., Inc.$26K
- Shire North American Group Inc$2K
What the payments were for
- Consulting fees$95,58787%
- Speaking & faculty fees$1500%
- Travel & lodging$7,2957%
- Food & beverage$1,9292%
- Education$5,5285%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sarepta Therapeutics, Inc. | 43 | $64,031 |
| Amicus Therapeutics, Inc. | 9 | $18,513 |
| Sanofi | 3 | $11,116 |
| Spark Therapeutics, Inc. | 5 | $6,984 |
| UCB, Inc. | 6 | $2,930 |
| Lupin Inc. | 1 | $2,925 |
| Applied Therapeutics, Inc. | 2 | $1,620 |
| Vertex | 3 | $1,250 |
| Jazz Pharmaceuticals Inc. | 1 | $600 |
| AstraZeneca | 3 | $287 |
| Akorn, Inc. | 11 | $123 |
| Ultragenyx Pharmaceutical Inc. | 2 | $60 |
| Tanabe Pharma America, Inc. | 1 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few neuromuscular medicine providers in Texasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 16 | $360,337 |
| Mycophenolate Mofetil | 41 | $4,993 |
| Pyridostigmine Bromide | 49 | $4,652 |
| Azathioprine | 13 | $1,797 |
| Prednisone | 48 | $504 |
| Diazepam | 11 | $174 |
Paid to pharmacies, not to this prescriber.
Other neuromuscular medicine in San Antonio
- Ratna Bhavaraju SankaSan Antonio$56K
- Cassie ChanSan Antonio$2K
- John SladkySan Antonio$29
- Yessar HussainAustin$127K
- Ashley AndersonHouston$76K
- Suur BilicilerHouston$37K
- Hakam AsaadDallas$8K
- Darine KassarSugar Land$6K
- Niloofar YariDallas$5K
- Anita MadanHouston$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.